Literature DB >> 17898709

Pharmacologic advances in the global control and treatment of malaria: combination therapy and resistance.

M M Nyunt1, C V Plowe.   

Abstract

Combination drug therapy for malaria is recommended both to prevent and to overcome drug resistance. Drug combinations developed for use in Asia are being deployed in Africa, where higher rates of malaria affect the therapeutic and public health objectives of malaria chemotherapy as well as drug safety. Rational consideration of drug mechanisms, pharmacokinetics (PK), pharmacodynamics (PD), and malaria epidemiology should result in more effective combination regimens that retain therapeutic and prophylactic efficacy in the face of resistance.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17898709     DOI: 10.1038/sj.clpt.6100361

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  20 in total

1.  Population pharmacokinetics and pharmacodynamic considerations of amodiaquine and desethylamodiaquine in Kenyan adults with uncomplicated malaria receiving artesunate-amodiaquine combination therapy.

Authors:  Vincent Jullien; Bernhards Ogutu; Elizabeth Juma; Gwenaelle Carn; Charles Obonyo; Jean-René Kiechel
Journal:  Antimicrob Agents Chemother       Date:  2010-04-05       Impact factor: 5.191

2.  Antiplasmodial activity of sesquiterpene lactones and a sucrose ester from Vernonia guineensis Benth. (Asteraceae).

Authors:  Ngeh J Toyang; Michael A Krause; Rick M Fairhurst; Pierre Tane; Joseph Bryant; Rob Verpoorte
Journal:  J Ethnopharmacol       Date:  2013-03-27       Impact factor: 4.360

3.  Mefloquine damage vestibular hair cells in organotypic cultures.

Authors:  Dongzhen Yu; Dalian Ding; Haiyan Jiang; Daniel Stolzberg; Richard Salvi
Journal:  Neurotox Res       Date:  2010-09-22       Impact factor: 3.911

4.  No evidence of delayed parasite clearance after oral artesunate treatment of uncomplicated falciparum malaria in Mali.

Authors:  Amelia W Maiga; Bakary Fofana; Issaka Sagara; Demba Dembele; Antoine Dara; Oumar Bila Traore; Sekou Toure; Kassim Sanogo; Souleymane Dama; Bakary Sidibe; Aminatou Kone; Mahamadou A Thera; Christopher V Plowe; Ogobara K Doumbo; Abdoulaye A Djimde
Journal:  Am J Trop Med Hyg       Date:  2012-07       Impact factor: 2.345

5.  Monitoring antimalarial drug efficacy: current challenges.

Authors:  Miriam K Laufer
Journal:  Curr Infect Dis Rep       Date:  2009-01       Impact factor: 3.725

Review 6.  Resistance to antimalarial drugs: molecular, pharmacologic, and clinical considerations.

Authors:  Mark A Travassos; Miriam K Laufer
Journal:  Pediatr Res       Date:  2009-05       Impact factor: 3.756

7.  Nitazoxanide: In vitro and in vivo drug effects against Trichuris muris and Ancylostoma ceylanicum, alone or in combination.

Authors:  Lucienne Tritten; Angelika Silbereisen; Jennifer Keiser
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2012-03-10       Impact factor: 4.077

8.  Return of chloroquine-susceptible falciparum malaria in Malawi was a reexpansion of diverse susceptible parasites.

Authors:  Miriam K Laufer; Shannon Takala-Harrison; Fraction K Dzinjalamala; O Colin Stine; Terrie E Taylor; Christopher V Plowe
Journal:  J Infect Dis       Date:  2010-09-01       Impact factor: 5.226

9.  A longitudinal trial comparing chloroquine as monotherapy or in combination with artesunate, azithromycin or atovaquone-proguanil to treat malaria.

Authors:  Miriam K Laufer; Phillip C Thesing; Fraction K Dzinjalamala; Osward M Nyirenda; Rhoda Masonga; Matthew B Laurens; Abbie Stokes-Riner; Terrie E Taylor; Christopher V Plowe
Journal:  PLoS One       Date:  2012-08-17       Impact factor: 3.240

10.  Emax model and interaction index for assessing drug interaction in combination studies.

Authors:  J Jack Lee; Heather Y Lin; Diane D Liu; Maiying Kong
Journal:  Front Biosci (Elite Ed)       Date:  2010-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.